NCT02035787View on ClinicalTrials.gov

Metformin With the Levonorgestrel-Releasing Intrauterine Device for the Treatment of Complex Atypical Hyperplasia (CAH) and Endometrial Cancer (EC) in Non-surgical Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 27, 2014

Primary Completion Date

October 12, 2023

Study Completion Date

April 12, 2024

Conditions
Complex Atypical HyperplasiaEndometrial Cancer
Interventions
DRUG

Metformin

Metformin added to standard non-surgical treatment with levonorgestrel-Releasing Intrauterine Device.

Trial Locations (2)

27599

Lineberger Comprehensive Cancer Center, Chapel Hill

45220

TriHealth, Cincinnati

All Listed Sponsors
collaborator

Golfers Against Cancer

UNKNOWN

lead

UNC Lineberger Comprehensive Cancer Center

OTHER

NCT02035787 - Metformin With the Levonorgestrel-Releasing Intrauterine Device for the Treatment of Complex Atypical Hyperplasia (CAH) and Endometrial Cancer (EC) in Non-surgical Patients | Biotech Hunter | Biotech Hunter